Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial
| Autor: | Ian Kemp, Christine Mars, Vikram Khanna, Adeel Shahzad, Rod Stables, Nick Curzen, Robert Cooper, Keith S. Wilson, Matthew Shaw |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Ticagrelor
medicine.medical_specialty Time Factors Prasugrel Platelet Aggregation Platelet Function Tests medicine.medical_treatment Myocardial Ischemia Hemorrhage 030204 cardiovascular system & hematology 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine P2Y12 Risk Factors Interquartile range Internal medicine Humans Medicine Bivalirudin 030212 general & internal medicine Randomized Controlled Trials as Topic business.industry Coronary Thrombosis Anticoagulants Percutaneous coronary intervention Clopidogrel Treatment Outcome Purinergic P2Y Receptor Antagonists Cardiology Cardiology and Cardiovascular Medicine business Prasugrel Hydrochloride Platelet Aggregation Inhibitors Mace medicine.drug |
| Zdroj: | EuroIntervention. 13:1931-1938 |
| ISSN: | 1774-024X |
| DOI: | 10.4244/eij-d-17-00408 |
| Popis: | AIMS The HEAT-PPCI trial compared bivalirudin and unfractionated heparin in patients undergoing primary percutaneous coronary intervention (PPCI). The aim of this study was to report pre-specified, secondary analyses comparing the effects of P2Y12 inhibiting agents on platelet reactivity and clinical events. METHODS AND RESULTS All patients received preprocedural oral antiplatelet therapy. During the early stages of the trial, the P2Y12 inhibitor of choice was prasugrel with some use of clopidogrel. Later, routine therapy switched to ticagrelor. For cases performed during working hours, multiple electrode aggregometry (MEA) was used to assess ADP-induced platelet aggregation at the end of the index procedure. The effect of P2Y12 inhibitors on the primary efficacy (major adverse cardiac events [MACE]) and safety (major bleeding) outcomes was assessed in all patients. Multiple logistic regression was used to adjust for differences in baseline characteristics. With MEA data from 469 patients, prasugrel therapy resulted in significantly greater suppression of ADP-induced platelet aggregation at 40 U (23, 78) (median; interquartile range [IQR]) when compared against ticagrelor 75 U (41, 100.75); p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|